Target Name: OPN1MW
NCBI ID: G2652
Review Report on OPN1MW Target / Biomarker Content of Review Report on OPN1MW Target / Biomarker
OPN1MW
Other Name(s): OPSG_HUMAN | MGC176615 | MGC198468 | CBBM | cone dystrophy 5 (X-linked) | COD5 | GOP | Green cone pigment | Green-sensitive opsin | green cone pigment | MGC198469 | Cone dystrophy 5 (X-linked) | Medium-wave-sensitive opsin 1 | green cone photoreceptor pigment | photopigment apoprotein | Medium-wave-sensitive opsin 2 | opsin 1 (cone pigments), medium-wave-sensitive | OPN1MW2 | MGC177321 | Photopigment apoprotein | OPN1MW1 | CBD | Opsin 1 (cone pigments), medium-wave-sensitive (color blindness, deutan) | GCP | Green cone photoreceptor pigment | opsin 1, medium wave sensitive | Opsin 1 medium-wave-sensitive | Opsin 1 cone pigments medium-wave-sensitive 2 | medium-wave-sensitive opsin 1-like | green-sensitive opsin | Opsin 1 (cone pigments), medium-wave-sensitive

OPN1MW: A Promising Drug Target and Biomarker for Cancer

OPN1MW, also known as OpsgHuman, is a drug target and a biomarker that is being studied for its potential in treating various diseases, including cancer. OPN1MW is a human monoclonal antibody that targets the protein Opsg, which is found on the surface of cancer cells.

The development of OPN1MW as a drug target and biomarker began in 2012 when a team of researchers at the University of California, San Diego discovered that Opsg was expressed in high levels in various types of cancer. The researchers then began to study the potential uses of OPN1MW as a drug target and biomarker.

One of the main reasons for the potential of OPN1MW as a drug target is its ability to selectively bind to Opsg on the surface of cancer cells. This is because Opsg is a protein that is expressed in high levels in cancer cells, but is not found in healthy cells. This allows OPN1MW to target cancer cells specifically and avoid harming healthy cells.

Another reason for the potential of OPN1MW as a drug target is its ability to trigger an immune response in the body. OPN1MW is a monoclonal antibody, which means that it is a specific type of antibody that is produced by the body. When OPN1MW binds to Opsg on the surface of a cancer cell, it can trigger an immune response that helps to destroy the cancer cell.

In addition to its potential as a drug target, OPN1MW has also been shown to be a potential biomarker for cancer. This is because it can be used to diagnose and monitor the progress of various types of cancer. For example, OPN1MW has been used to detect breast cancer in women and Opsg has been used as a biomarker for various types of cancer.

The use of OPN1MW as a drug target and biomarker is still in its early stages, but it holds great promise for the treatment of various types of cancer. In the future, OPN1MW may be used in combination with other treatments to improve outcomes for cancer patients.

In conclusion, OPN1MW is a drug target and biomarker that holds great promise for the treatment of various types of cancer. Its ability to selectively bind to Opsg and trigger an immune response makes it a promising target for cancer treatments. As further research is conducted, OPN1MW is likely to continue to be a valuable tool for the treatment of cancer.

Protein Name: Opsin 1, Medium Wave Sensitive

The "OPN1MW Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about OPN1MW comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

OPN1MW3 | OPN1SW | OPN3 | OPN4 | OPN5 | OPRD1 | OPRK1 | OPRL1 | OPRM1 | OPRPN | OPTC | OPTN | OR10A2 | OR10A3 | OR10A4 | OR10A5 | OR10A6 | OR10A7 | OR10AA1P | OR10AB1P | OR10AC1 | OR10AD1 | OR10AF1P | OR10AG1 | OR10AK1P | OR10C1 | OR10D1P | OR10D3 | OR10D4P | OR10G2 | OR10G3 | OR10G4 | OR10G7 | OR10G8 | OR10G9 | OR10H1 | OR10H2 | OR10H3 | OR10H4 | OR10H5 | OR10J1 | OR10J2P | OR10J3 | OR10J5 | OR10K1 | OR10K2 | OR10P1 | OR10Q1 | OR10R2 | OR10S1 | OR10T2 | OR10V1 | OR10W1 | OR10X1 | OR10Z1 | OR11A1 | OR11G2 | OR11H1 | OR11H12 | OR11H13P | OR11H2 | OR11H5P | OR11H6 | OR11H7 | OR11J2P | OR11J5P | OR11K2P | OR11L1 | OR11M1P | OR12D2 | OR12D3 | OR13A1 | OR13C2 | OR13C3 | OR13C4 | OR13C5 | OR13C8 | OR13C9 | OR13D1 | OR13F1 | OR13G1 | OR13H1 | OR13J1 | OR13Z2P | OR14A16 | OR14A2 | OR14C36 | OR14I1 | OR14J1 | OR14L1P | OR1A1 | OR1A2 | OR1B1 | OR1C1 | OR1D2 | OR1D4 | OR1D5 | OR1E1 | OR1E2 | OR1E3